{
  "extraction_metadata": {
    "timestamp": "2025-10-01T16:52:36.186417",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; RECIST 1.1; time from randomisation until disease progression or death from any cause), symptomatology (EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C), health status (EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, EQ-5D VAS), health-related quality of life (EORTC QLQ-C30 functional scales), adverse events (AEs; total), serious adverse events (SAEs), severe adverse events, discontinuation due to adverse events, interstitial lung disease (severe AE), liver disorders (severe AE), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE), side effects (PRO-CTCAE instrument)",
      "ChunksUsed": 25,
      "ContextTokens": 8793
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST v1.1), objective response rate (ORR), duration of response (DoR), time to response, disease control rate, adverse events (CTCAE v5.0), adverse events (CTCAE v4.03), treatment discontinuation due to adverse events, grade 3 or higher adverse events, EORTC QLQ-C30, EORTC QLQ-LC13, NSCLC-SAQ, PGIS, PGIC, PRO-CTCAE, item GP5 of the FACT-G, EQ-5D-5L, health-related quality of life (HRQoL), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 9716
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "objective response rate (ORR; RECIST 1.1, blinded independent central review), complete response (RECIST 1.1), partial response (RECIST 1.1), overall survival (OS), progression-free survival (PFS; RECIST 1.1), health-related quality of life, visual analogue scale (utility measurement), quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), adverse events (general), dose modifications, disutility for intravenous administration, time-to-death utilities, health-state utilities",
      "ChunksUsed": 25,
      "ContextTokens": 7892
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "progression-free survival (independent review panel; RECIST 1.1), overall survival, objective response rate (independent review panel; RECIST 1.1), duration of response (RECIST 1.1), disease control rate, time to response, adverse events (general), serious adverse events, adverse events grade ≥3, EORTC QLQ-C30, EORTC QLQ-LC13",
      "ChunksUsed": 25,
      "ContextTokens": 8580
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "",
      "ChunksUsed": 5,
      "ContextTokens": 1715
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), serious adverse events (SAEs), treatment-related adverse events leading to discontinuation, treatment-associated events resulting in death, grade ≥ 3 treatment-related adverse events, adverse events (general), diarrhoea, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), fatigue, weight loss, anaemia, oral cavity blockage, asthenia, constipation, neutropenia, peripheral neuropathy, fever, peripheral oedema, shortness of breath, cough, vomiting, decreased appetite, increased asparaginase aminotransferase activity, abdominal pain, joint pain, back pain, headache, alopecia, quality of life (general), EORTC QLQ-C30, EORTC QLQ-LC13, years of life gained (LYG), quality-adjusted life years (QALY), cost-effectiveness (incremental cost-utility ratio, ICUR), budget impact analysis",
      "ChunksUsed": 19,
      "ContextTokens": 6842
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST v1.1), objective response rate (ORR), duration of response (DoR), disease control rate, time to response, event-free survival, time to progression, time to next treatment, duration of treatment, dropout rate, adverse events (Common Terminology Criteria for Adverse Events, CTCAE v5.0), adverse event rate, serious adverse events (grade 3-4), mortality-related toxicity, morbidity and mortality associated with clinical events, chest pain, dyspnoea, cough, EORTC QLQ-C30, EQ-5D-5L, visual analogue scale, physical functioning, overall health status, time to deterioration of overall health status, time to deterioration of physical functioning, quality of life",
      "ChunksUsed": 25,
      "ContextTokens": 8757
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "progression-free survival (PFS), overall survival (OS), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY), health-related quality of life (measured by time to death)",
      "ChunksUsed": 19,
      "ContextTokens": 5632
    }
  }
}